Health product manufacturer Blackmores had a very weak September quarter and does not expect to match its FY16 performance in FY17.

Sigma Pharmaceuticals is expanding its reach into hospital pharmacy while maintaining a stable base business. Brokers welcome the increased diversity.

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. After a regulation-risk price plunge of questionable magnitude, Blackmores is again offering value according to Credit Suisse.

FNArena Editor Rudi Filapek-Vandyck discusses the impact of speculators on share prices for Blackmores and others.

A brief look at important company events and economic data releases next week.

The past nine months have been brutal for many investment portfolios, but not all stocks are equal.

Vitamin and sports nutrition manufacturer, Vitaco Holdings, has piqued the interest of several brokers, as it ramps up its marketing intensity in China in Blackmores’ footsteps.

The latest agreement between the government and the pharmacy industry involves cuts to the PBS and a subsequent drag on pharmacy company earnings, with Sigma and API among those impacted.

Australian Pharmaceutical Industries impressed brokers with its retail expansion but uncertainties prevail in its wholesale division.

Weekly update on recommendation, target price, and earnings forecast changes.